Rhogenites integrates Artificial Intelligence, Protein Engineering, and Synthetic Biology to create de novo proteins and engineered live biotherapeutics.
View Our TechnologyOur Vision: To redefine the boundaries of modern medicine by engineering biology itself. We envision a future where systemic infections, chronic inflammation, and neurodegeneration are not just managed, but treated with precision-designed, de novo therapeutics that are accessible to patients globally.
Our Mission: Rhogenites is dedicated to translating advanced scientific innovation into accessible healthcare solutions. By building a world-class team and harnessing the convergence of AI and Synthetic Biology, we develop next-generation therapeutics, diagnostics, and preventive platforms for critical global health challenges.
We do not rely on discovery by chance. We use generative AI and rational design to engineer proteins with functions not found in nature.
Our fusion proteins and genetic circuits are designed to act strictly at the site of disease, minimizing systemic toxicity.
We are committed to developing cost-effective solutions, such as our point-of-care TB diagnostics, for resource-limited settings.
The Challenge: Systemic infections often lead to Multi-Organ Dysfunction Syndrome (MODS) driven by a cytokine storm.
Our Approach: Designing novel chimeric fusion proteins engineered to neutralize key pathogenic and inflammatory mediators. By targeting specific upstream pathways, our candidates aim to dampen the hyper-inflammatory response.
The Challenge: Conventional treatments for gut inflammation and neoplastic conditions often lack localized specificity.
Our Approach: Utilizing synthetic biology, we engineer next-generation probiotic strains to act as living medicine. These strains are programmed to sense disease markers and secrete therapeutic proteins directly at the site of inflammation.
The Challenge: Identifying viable targets for conditions characterized by protein misfolding and neuronal loss.
Our Approach: Employing AI-driven molecular docking and screening to identify novel small-molecule candidates. Our research focuses on modulating pathways involved in neuroprotection and clearing pathological protein aggregates.
The Challenge: Rapid, reliable, and low-cost diagnosis of Tuberculosis in resource-limited settings.
Our Approach: Developing a non-invasive diagnostic platform utilizing micro-fluidics and advanced biosensing to detect specific TB biomarkers with high sensitivity.
The core engines driving our discovery.
Utilizing deep learning and transformer models to design de novo protein backbones with atom-level precision. Our platform optimizes for superior thermodynamic stability, solubility, and "zero immunogenicity" via automated epitope masking and developability assessment.
Rational assembly of multi-specific fusion proteins, combining high-affinity targeting domains with potent effector warheads. We employ flexible linker libraries to ensure optimal folding and steric freedom, unlocking novel mechanisms of action against complex targets.